Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

An Observational Study to Evaluate the Safety of the Combination Therapy of Genexol PM and Carboplatin as First-line Therapy for Ovarian Cancer Patients

To evaluate the safety profile of Genexol PM combination with carboplatin for patients with newly diagnosed ovarian cancer. We hypothesized Genexol PM can be safely administered to newly diagnosed ovarian cancer patients compared to conventional paclitaxel/carboplatin combination therapy. Therefore, we will compare the prospective cohort with a historical comparison with patients administered paclitaxel/carboplatin and paclitaxel/carboplatin/bevacizumab combination therapy.

Inclusion Criteria:

• Age over 18
• Patients consented to participate
• Pathologically diagnosed ovarian cancer FIGO stage IC-IVB
• ECOG 0-2
• Patients with an expected survival of 3 months or more

Exclusion Criteria:

• History of paclitaxel or carboplatin hypersensitivity
• Inadequate bone marrow function (Neutrophil<1500/mm3, Platelet <100,000/mm3)
• Pregnancy or breast-feeding state
• Metachronous or synchronous malignancy
• Galactose intolerance, Lapp Lactase deficiency, or glucose-galactose malabsorption patients with genetic problems
• Other patients who were judged difficult to be included in this investigation by the investigator in charge